An Efficacy And Safety Study of CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01909427 |
Recruitment Status :
Completed
First Posted : July 26, 2013
Last Update Posted : March 2, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Rheumatoid Arthritis | Drug: Placebo Drug: CNTO 6785 200 mg Drug: CNTO 6785 100 mg Drug: CNTO 6785 50 mg Drug: CNTO 6785 15 mg Drug: Methotrexate (MTX) | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 257 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Placebo-controlled Double-blind, Multicenter, Phase 2 Dose Ranging Study To Assess The Efficacy And Safety of CNTO 6785 In Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy |
Study Start Date : | June 2013 |
Actual Primary Completion Date : | December 2014 |
Actual Study Completion Date : | May 2015 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: Placebo/CNTO 6785 200 mg+Methotrexate (MTX) |
Drug: Placebo
Placebo subcutaneous injections (SC) every 4 weeks through Week 12 Drug: CNTO 6785 200 mg CNTO 6785 200 mg SC every 4 weeks from Week 16 through Week 28 Drug: Methotrexate (MTX) MTX at the same stable dose through Week 32, that participants were receiving prior to screening. |
Experimental: CNTO 6785 200 mg+MTX |
Drug: CNTO 6785 200 mg
CNTO 6785 200 mg SC every 4 weeks through Week 28 Drug: Methotrexate (MTX) MTX at the same stable dose through Week 32, that participants were receiving prior to screening. |
Experimental: CNTO 6785 100 mg+MTX |
Drug: CNTO 6785 100 mg
CNTO 6785 100 mg SC every 4 weeks through Week 28 Drug: Methotrexate (MTX) MTX at the same stable dose through Week 32, that participants were receiving prior to screening. |
Experimental: CNTO 6785 50 mg+MTX |
Drug: CNTO 6785 50 mg
CNTO 6785 50 mg SC every 4 weeks through Week 28 Drug: Methotrexate (MTX) MTX at the same stable dose through Week 32, that participants were receiving prior to screening. |
Experimental: CNTO 6785 15 mg+MTX |
Drug: CNTO 6785 15 mg
CNTO 6785 15 mg SC every 4 weeks through Week 28 Drug: Methotrexate (MTX) MTX at the same stable dose through Week 32, that participants were receiving prior to screening. |
- The proportion of participants who achieve an ACR 20 response at Week 16 [ Time Frame: Week 16 ]American College of Rheumatology (ACR) 20 response is a >=20% improvement in rheumatoid arthritis (RA) symptoms.
- Change from baseline in DAS28 (CRP) at Week 16 [ Time Frame: Baseline to Week 16 ]DAS28 (using CRP [C-reactive protein]) is a measure of tender and swollen joints and the patient's assessment of disease activity.
- The proportion of participants who achieve ACR 50 response at Week 16 [ Time Frame: Week 16 ]American College of Rheumatology (ACR) 50 response is a >=50% improvement in rheumatoid arthritis (RA) symptoms.
- The proportion of participants who achieve ACR 20 response through Week 32 [ Time Frame: Week 32 ]
- The proportion of participants who achieve ACR 50 response through Week 32 [ Time Frame: Week 32 ]
- The proportion of participants who achieve ACR 70 response through Week 32 [ Time Frame: Week 32 ]American College of Rheumatology (ACR) 70 response is a >=70% improvement in rheumatoid arthritis (RA) symptoms.
- Change from baseline of DAS28 (CRP) through Week 32 [ Time Frame: Baseline to Week 32 ]
- The proportion of participants with DAS28 (CRP) response through Week 32 [ Time Frame: Week 32 ]DAS28 (using CRP [C-reactive protein]) response is improvement from baseline, with >1.2 indicating a good or moderate response and <=0.6 indicating no response.
- The proportion of participants with DAS28 (CRP) remission at Week 16 [ Time Frame: Week 16 ]DAS28 (using CRP [C-reactive protein]) remission is defined as a value of <2.6 on the Disease Activity Index, a measure of tender and swollen joints and the patient's assessment of disease activity.
- The proportion of participants with DAS28 (CRP) remission at Week 32 [ Time Frame: Week 32 ]
- Change from baseline in DAS28 (ESR) at Week 16 [ Time Frame: Baseline to Week 16 ]DAS28 (using erythrocyte sedimentation rate) is a measure of tender and swollen joints and the patient's assessment of disease activity.
- Change from baseline in DAS28 (ESR) at Week 32 [ Time Frame: Baseline to Week 32 ]
- Change from baseline in HAQ-DI score through Week 32 [ Time Frame: Baseline to Week 32 ]The Health Assessment Questionnaire-Disability Index (HAQ-DI) assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas, each scored from 0 (no difficulty) to 3 (inability to perform a task).
- Change from baseline in SF-36 at Week 16 [ Time Frame: Baseline to Week 16 ]The SF-36 is a medical outcome study health measure and consists of 8 multi-item scales that are scored from 0 to 100, with higher scores indicating better health.
- Change from baseline in SF-36 at Week 32 [ Time Frame: Baseline to Week 32 ]
- Change from baseline in CDAI at Week 16 [ Time Frame: Baseline to Week 16 ]Clinical Disease Activity Index (CDAI) score is a derived score combining tender joints (28 joints), swollen joints (28 joints), Patient's Global Assessment of Disease Activity, and Physician's Global Assessments of Disease Activity.
- Change from baseline in CDAI at Week 32 [ Time Frame: Baseline to Week 32 ]
- Change from baseline in SDAI at Week 16 [ Time Frame: Baseline to Week 16 ]The Simplified Disease Activity Index (SDAI) score is a derived score combining tender joints (28 joints), swollen joints (28 joints), Patient's Global Assessment of Disease Activity, Physician's Global Assessments of Disease Activity, and CRP.
- Change from baseline in SDAI at Week 32 [ Time Frame: Baseline to Week 32 ]
- The proportion of participants with SDAI-based ACR/EULAR remission at Week 16 [ Time Frame: Week 16 ]The Simplified Disease Activity Index (SDAI)-based ACR/EULAR (European League Against Rheumatism) remission is defined as a SDAI value of <=3.3 at a visit.
- The proportion of participants with SDAI-based ACR/EULAR remission at Week 32 [ Time Frame: Week 32 ]
- The proportion of participants with Boolean-based ACR/EULAR remission at Week 16 [ Time Frame: Week 16 ]Boolean-based ACR/EULAR remission is achieved if all of the following 4 criteria at that visit are met: tender joint count (68 joints) <=1; swollen joint count (66 joints) <=1; CRP <=1 mg/dL; and Patient's Global Assessment of Disease Activity on VAS <=1 on a 0 to 10 scale.
- The proportion of participants with Boolean-based ACR/EULAR remission at Week 32 [ Time Frame: Week 32 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Have a diagnosis of rheumatoid arthritis (RA) (according to the revised 1987 criteria of the American Rheumatism Association) and have had RA for at least 6 months prior to the date of signing the informed consent at screening
- Have active RA defined study as persistent disease activity with both of the following criteria: at least 6 swollen and 6 tender joints using a 66/68 joint count at the time of screening and at baseline; and serum C-reactive protein (CRP) ≥ 0.8 mg/dL at screening or erythrocyte sedimentation rate (ESR) ≥ 28 mm in the first hour at screening or baseline
- Have been treated with and tolerated methotrexate (MTX) treatment at dosages from 7.5 to 25 mg/week, inclusive, for a minimum of 6 months prior to screening and must have a stable MTX dose for a minimum of 6 weeks prior to the first dosing with study agent
Exclusion Criteria:
- Has inflammatory diseases other than RA, that might confound the evaluation of the benefit of study agent therapy
- Has a diagnosis of fibromyalgia
- Has a recent history (within 12 months prior to screening) of uncontrolled, chronic disease including, but not limited to, pulmonary, psychiatric, and metabolic disturbances, cardiovascular, endocrine, neurological, hepatic, gastrointestinal, renal, hematological, or urological diseases that the investigator believes are clinically significant
- At screening, the results of laboratory tests must meet protocol-specified criteria
- Has ever received any approved or investigational biologic agent for a rheumatic indication

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01909427
Argentina | |
Buenos Aires, Argentina | |
Ciudad Autonoma Buenos Aires, Argentina | |
Cordoba, Argentina | |
La Capital, Argentina | |
San Juan, Argentina | |
Colombia | |
Barranquilla, Colombia | |
Bogota, Colombia | |
Medellín, Colombia | |
Czech Republic | |
Jihlava, Czech Republic | |
Praha 5, Czech Republic | |
Praha, Czech Republic | |
Philippines | |
Cebu, Philippines | |
Iloilo City, Philippines | |
Lipa City, Philippines | |
Quezon City, Philippines | |
Poland | |
Bydgoszcz, Poland | |
Grodzisk Mazowiecki, Poland | |
Lodz, Poland | |
Lublin, Poland | |
Poznan, Poland | |
Warszawa, Poland | |
Wroclaw, Poland | |
Russian Federation | |
Barnaul, Russian Federation | |
Ekaterinburg, Russian Federation | |
Kemerovo, Russian Federation | |
Kursk, Russian Federation | |
Moscow, Russian Federation | |
Novosibirsk, Russian Federation | |
Petrozavodsk, Russian Federation | |
Saint-Petersburg, Russian Federation | |
St. Petersburg, Russian Federation | |
Yaroslavl, Russian Federation | |
Thailand | |
Bangkok, Thailand | |
Chiang Mai, Thailand |
Study Director: | Janssen Research & Development, LLC Clinical Trial | Janssen Research & Development, LLC |
Responsible Party: | Janssen Research & Development, LLC |
ClinicalTrials.gov Identifier: | NCT01909427 |
Other Study ID Numbers: |
CR100935 CNTO6785ARA2001 ( Other Identifier: Janssen Research & Development, LLC ) 2012-003629-40 ( EudraCT Number ) |
First Posted: | July 26, 2013 Key Record Dates |
Last Update Posted: | March 2, 2016 |
Last Verified: | February 2016 |
Active rheumatoid arthritis despite methotrexate therapy CNTO 6785 Methotrexate |
Arthritis Arthritis, Rheumatoid Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Connective Tissue Diseases Autoimmune Diseases Immune System Diseases Methotrexate Abortifacient Agents, Nonsteroidal Abortifacient Agents Reproductive Control Agents |
Physiological Effects of Drugs Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Dermatologic Agents Enzyme Inhibitors Folic Acid Antagonists Immunosuppressive Agents Immunologic Factors Antirheumatic Agents Nucleic Acid Synthesis Inhibitors |